FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211690713> ?p ?o ?g. }

• W3211690713 endingPage "S165" @default.
• W3211690713 startingPage "S165" @default.
• W3211690713 abstract "Background Pomalidomide (POM) with dexamethasone (DEX) is approved in patients (pts) with relapsed and refractory (RRMM) myeloma and achieved a progression free survival (PFS) between 4.0 and 4.6 months in two pivotal phase III trials (MM-003 and MM-010). In addition, POM-DEX is a current standard backbone for triplet combinations in RRMM. However, POM-DEX with registered POM dosing (4mg daily, 21/28 day cycle) has significant toxicity with G3/4 neutropenia (48%), anemia (33%), infections (34%) and thrombocytopenia (22%) in MM-003, and up to 85% G3/4 neutropenia in triplets containing CD38 antibodies. The relationship between dose, efficacy and toxicity of POM is poorly established and POM delivered on a 2mg daily continuous schedule was similarly active compared to the standard schedule, but less toxic. Half life time of POM (7.5h) is significantly longer compared to lenalidomide (3h) with a slow decline of the POM plasma concentration at the terminal phase. Alternate day dosing of POM 4mg may therefore maintain efficacy while mitigating toxicity. This multicenter, open label, non-randomized phase II study investigated the activity and toxicity of POM 4mg given continuously every second day in RRMM pts. Methods Inclusion criteria matched MM-003. Pts with RRMM must have had ≥ 2 prior lines including bortezomib (BORT), lenalidomide (LEN), adequate alkylator treatment, and progressive myeloma on or within 60 days of the last MM treatment. Continuous oral POM 4mg on alternate days 1 to 28 was combined with weekly oral DEX 40mg (pts > 75 years 20mg) until intolerance or progression (PD). Pts received prophylaxis with acyclovir/valacyclovir, cotrimoxazole and ASS. Prophylactic G-CSF was not allowed. Primary endpoint was overall response rate (ORR, minimal response (MR) or better by IMWG criteria). Secondary objectives were overall survival (OS), 12 months OS, PFS and adverse events (AE). Results 34 patients were enrolled (median age 75 yrs, range 52-87) with time from diagnosis of 5.1 yrs (range 1.9-16.8). Prior treatments included LEN (100%), BORT (100%), alkylator (100%), carfilzomib (29%) and daratumumab (27%); 14 (41%) pts had high-risk cytogenetic features. Median treatment duration was 3.6 months. G3/4 AE occurred in less than one quarter of patients: (neutropenia 24%; anemia 18%; infections 18%; thrombocytopenia 12%). Neutropenic fever was not observed. ORR was 29 % (95% confidence interval [CI], 16%-50%; 3 (9%) VGPRs, 6 (8%) PRs and 1 (3%) MR; 15 pts (44%) achieved SD. 9 pts (26%) progressed. Median PFS was 4.2 months (95% CI, 1.9-5.5 months). OS at 12 months was 66.5% (95% CI, 47.6-79.9). Conclusion POM 4mg on an alternate day continuous dosing schedule is an active and well-tolerated option to deliver POM-DEX to RRMM pts and is especially reasonable for patients at increased risk of toxicity. This dosing schedule may have comparable efficacy, improved safety and should be explored in triplet combination. Pomalidomide (POM) with dexamethasone (DEX) is approved in patients (pts) with relapsed and refractory (RRMM) myeloma and achieved a progression free survival (PFS) between 4.0 and 4.6 months in two pivotal phase III trials (MM-003 and MM-010). In addition, POM-DEX is a current standard backbone for triplet combinations in RRMM. However, POM-DEX with registered POM dosing (4mg daily, 21/28 day cycle) has significant toxicity with G3/4 neutropenia (48%), anemia (33%), infections (34%) and thrombocytopenia (22%) in MM-003, and up to 85% G3/4 neutropenia in triplets containing CD38 antibodies. The relationship between dose, efficacy and toxicity of POM is poorly established and POM delivered on a 2mg daily continuous schedule was similarly active compared to the standard schedule, but less toxic. Half life time of POM (7.5h) is significantly longer compared to lenalidomide (3h) with a slow decline of the POM plasma concentration at the terminal phase. Alternate day dosing of POM 4mg may therefore maintain efficacy while mitigating toxicity. This multicenter, open label, non-randomized phase II study investigated the activity and toxicity of POM 4mg given continuously every second day in RRMM pts. Inclusion criteria matched MM-003. Pts with RRMM must have had ≥ 2 prior lines including bortezomib (BORT), lenalidomide (LEN), adequate alkylator treatment, and progressive myeloma on or within 60 days of the last MM treatment. Continuous oral POM 4mg on alternate days 1 to 28 was combined with weekly oral DEX 40mg (pts > 75 years 20mg) until intolerance or progression (PD). Pts received prophylaxis with acyclovir/valacyclovir, cotrimoxazole and ASS. Prophylactic G-CSF was not allowed. Primary endpoint was overall response rate (ORR, minimal response (MR) or better by IMWG criteria). Secondary objectives were overall survival (OS), 12 months OS, PFS and adverse events (AE). 34 patients were enrolled (median age 75 yrs, range 52-87) with time from diagnosis of 5.1 yrs (range 1.9-16.8). Prior treatments included LEN (100%), BORT (100%), alkylator (100%), carfilzomib (29%) and daratumumab (27%); 14 (41%) pts had high-risk cytogenetic features. Median treatment duration was 3.6 months. G3/4 AE occurred in less than one quarter of patients: (neutropenia 24%; anemia 18%; infections 18%; thrombocytopenia 12%). Neutropenic fever was not observed. ORR was 29 % (95% confidence interval [CI], 16%-50%; 3 (9%) VGPRs, 6 (8%) PRs and 1 (3%) MR; 15 pts (44%) achieved SD. 9 pts (26%) progressed. Median PFS was 4.2 months (95% CI, 1.9-5.5 months). OS at 12 months was 66.5% (95% CI, 47.6-79.9). POM 4mg on an alternate day continuous dosing schedule is an active and well-tolerated option to deliver POM-DEX to RRMM pts and is especially reasonable for patients at increased risk of toxicity. This dosing schedule may have comparable efficacy, improved safety and should be explored in triplet combination." @default.
• W3211690713 created "2021-11-22" @default.
• W3211690713 creator A5008923097 @default.
• W3211690713 creator A5013803774 @default.
• W3211690713 creator A5014734060 @default.
• W3211690713 creator A5018939058 @default.
• W3211690713 creator A5020563845 @default.
• W3211690713 creator A5022000387 @default.
• W3211690713 creator A5041335829 @default.
• W3211690713 creator A5044479977 @default.
• W3211690713 creator A5045139107 @default.
• W3211690713 creator A5046713117 @default.
• W3211690713 creator A5049979514 @default.
• W3211690713 creator A5050974067 @default.
• W3211690713 creator A5052238969 @default.
• W3211690713 creator A5073165908 @default.
• W3211690713 creator A5074884602 @default.
• W3211690713 date "2021-10-01" @default.
• W3211690713 modified "2023-09-27" @default.
• W3211690713 title "P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study)" @default.
• W3211690713 doi "https://doi.org/10.1016/s2152-2650(21)02354-5" @default.
• W3211690713 hasPublicationYear "2021" @default.
• W3211690713 type Work @default.
• W3211690713 sameAs 3211690713 @default.
• W3211690713 citedByCount "0" @default.
• W3211690713 crossrefType "journal-article" @default.
• W3211690713 hasAuthorship W3211690713A5008923097 @default.
• W3211690713 hasAuthorship W3211690713A5013803774 @default.
• W3211690713 hasAuthorship W3211690713A5014734060 @default.
• W3211690713 hasAuthorship W3211690713A5018939058 @default.
• W3211690713 hasAuthorship W3211690713A5020563845 @default.
• W3211690713 hasAuthorship W3211690713A5022000387 @default.
• W3211690713 hasAuthorship W3211690713A5041335829 @default.
• W3211690713 hasAuthorship W3211690713A5044479977 @default.
• W3211690713 hasAuthorship W3211690713A5045139107 @default.
• W3211690713 hasAuthorship W3211690713A5046713117 @default.
• W3211690713 hasAuthorship W3211690713A5049979514 @default.
• W3211690713 hasAuthorship W3211690713A5050974067 @default.
• W3211690713 hasAuthorship W3211690713A5052238969 @default.
• W3211690713 hasAuthorship W3211690713A5073165908 @default.
• W3211690713 hasAuthorship W3211690713A5074884602 @default.
• W3211690713 hasConcept C126322002 @default.
• W3211690713 hasConcept C143998085 @default.
• W3211690713 hasConcept C2776063141 @default.
• W3211690713 hasConcept C2776364478 @default.
• W3211690713 hasConcept C2777063308 @default.
• W3211690713 hasConcept C2777288759 @default.
• W3211690713 hasConcept C2778524551 @default.
• W3211690713 hasConcept C2778850193 @default.
• W3211690713 hasConcept C2780401358 @default.
• W3211690713 hasConcept C29730261 @default.
• W3211690713 hasConcept C71924100 @default.
• W3211690713 hasConcept C90924648 @default.
• W3211690713 hasConcept C98274493 @default.
• W3211690713 hasConceptScore W3211690713C126322002 @default.
• W3211690713 hasConceptScore W3211690713C143998085 @default.
• W3211690713 hasConceptScore W3211690713C2776063141 @default.
• W3211690713 hasConceptScore W3211690713C2776364478 @default.
• W3211690713 hasConceptScore W3211690713C2777063308 @default.
• W3211690713 hasConceptScore W3211690713C2777288759 @default.
• W3211690713 hasConceptScore W3211690713C2778524551 @default.
• W3211690713 hasConceptScore W3211690713C2778850193 @default.
• W3211690713 hasConceptScore W3211690713C2780401358 @default.
• W3211690713 hasConceptScore W3211690713C29730261 @default.
• W3211690713 hasConceptScore W3211690713C71924100 @default.
• W3211690713 hasConceptScore W3211690713C90924648 @default.
• W3211690713 hasConceptScore W3211690713C98274493 @default.
• W3211690713 hasLocation W32116907131 @default.
• W3211690713 hasOpenAccess W3211690713 @default.
• W3211690713 hasPrimaryLocation W32116907131 @default.
• W3211690713 hasRelatedWork W1968654086 @default.
• W3211690713 hasRelatedWork W2051109119 @default.
• W3211690713 hasRelatedWork W2128903704 @default.
• W3211690713 hasRelatedWork W2400769328 @default.
• W3211690713 hasRelatedWork W2470833619 @default.
• W3211690713 hasRelatedWork W2590875813 @default.
• W3211690713 hasRelatedWork W2614781853 @default.
• W3211690713 hasRelatedWork W2792859185 @default.
• W3211690713 hasRelatedWork W2806380367 @default.
• W3211690713 hasRelatedWork W2980591007 @default.
• W3211690713 hasVolume "21" @default.
• W3211690713 isParatext "false" @default.
• W3211690713 isRetracted "false" @default.
• W3211690713 magId "3211690713" @default.
• W3211690713 workType "article" @default.